These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37398189)

  • 1. 14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity.
    Pattanayak R; Petit CM; Yacoubian TA
    bioRxiv; 2023 May; ():. PubMed ID: 37398189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity and toxicity.
    Pattanayak R; Ekkatine R; Petit CM; Yacoubian TA
    Hum Mol Genet; 2024 Nov; 33(23):2071-2083. PubMed ID: 39324210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.
    Slone SR; Lavalley N; McFerrin M; Wang B; Yacoubian TA
    Neurobiol Dis; 2015 Jul; 79():1-13. PubMed ID: 25862939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.
    Fan Y; Nirujogi RS; Garrido A; Ruiz-Martínez J; Bergareche-Yarza A; Mondragón-Rezola E; Vinagre-Aragón A; Croitoru I; Gorostidi Pagola A; Paternain Markinez L; Alcalay R; Hickman RA; Düring J; Gomes S; Pratuseviciute N; Padmanabhan S; Valldeoriola F; Pérez Sisqués L; Malagelada C; Ximelis T; Molina Porcel L; Martí MJ; Tolosa E; Alessi DR; Sammler EM
    Acta Neuropathol; 2021 Sep; 142(3):475-494. PubMed ID: 34125248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues.
    Iannotta L; Biosa A; Kluss JH; Tombesi G; Kaganovich A; Cogo S; Plotegher N; Civiero L; Lobbestael E; Baekelandt V; Cookson MR; Greggio E
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105882
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
    Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax.
    Slone SR; Lesort M; Yacoubian TA
    PLoS One; 2011; 6(7):e21720. PubMed ID: 21799745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.
    Ito G; Katsemonova K; Tonelli F; Lis P; Baptista MA; Shpiro N; Duddy G; Wilson S; Ho PW; Ho SL; Reith AD; Alessi DR
    Biochem J; 2016 Sep; 473(17):2671-85. PubMed ID: 27474410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner.
    Kania E; Long JS; McEwan DG; Welkenhuyzen K; La Rovere R; Luyten T; Halpin J; Lobbestael E; Baekelandt V; Bultynck G; Ryan KM; Parys JB
    Cell Death Dis; 2023 Jul; 14(7):436. PubMed ID: 37454104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
    Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR
    PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain.
    Singh V; Menard MA; Serrano GE; Beach TG; Zhao HT; Riley-DiPaolo A; Subrahmanian N; LaVoie MJ; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2023 Dec; 11(1):201. PubMed ID: 38110990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.
    Fernández B; Chittoor-Vinod VG; Kluss JH; Kelly K; Bryant N; Nguyen APT; Bukhari SA; Smith N; Lara Ordóñez AJ; Fdez E; Chartier-Harlin MC; Montine TJ; Wilson MA; Moore DJ; West AB; Cookson MR; Nichols RJ; Hilfiker S
    J Parkinsons Dis; 2022; 12(5):1423-1447. PubMed ID: 35599495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease.
    Karayel Ö; Tonelli F; Virreira Winter S; Geyer PE; Fan Y; Sammler EM; Alessi DR; Steger M; Mann M
    Mol Cell Proteomics; 2020 Sep; 19(9):1546-1560. PubMed ID: 32601174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.